Supriya Lifescience · NSE: SUPRIYA · BSE: 543434
Q4 FY24 results · Jan–Mar 2024
Supriya Lifescience reported revenue from operations of ₹158.18 crore (up 11.2% from Q4 FY23) and net profit of ₹36.93 crore (down 3.4% from Q4 FY23) for Q4 FY24 (Jan–Mar 2024), on a standalone basis.
| Item | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 158.18 | 142.27 | +11.2% | 140.07 | +12.9% |
| Other income | 2.19 | 1.96 | +11.3% | 3.06 | −28.7% |
| Total income | 160.37 | 144.23 | +11.2% | 143.14 | +12.0% |
| Profit before tax | 53.17 | 53.29 | −0.2% | 40.10 | +32.6% |
| Net profit for the period | 36.93 | 38.23 | −3.4% | 29.79 | +24.0% |
| EPS, basic (₹) | 4.59 | 4.75 | −3.4% | 3.70 | +24.1% |
| Net margin (%) | 23.3 | 26.9 | 21.3 |
Standalone
- Filed with BSE
- 11 Jun 2024, 12:48 IST
- Board meeting
- 28 May 2024
- Period
- 01 Jan 2024 to 31 Mar 2024
- Review status
- Audited
- Source
- XBRL filing on BSE